Savsu to supply Novartis’ newly-approved SMA treatment

By Vassia Barba

- Last updated on GMT

(Image: Getty/ClaireMcAdams
(Image: Getty/ClaireMcAdams

Related tags Novartis Savsu Technologies AveXis Zolgensma

Novartis to continue with AveXis’ adoption of Savsu’s evo cold chain management technology for newly-approved gene therapy.

Savsu Technologies, a New Mexico, US-based company, which creates temperature controlled systems and transport containers developed the evo Cold Chain 2.0 system especially for cell and gene therapies shipments.

Evo ‘smart shippers’ of the Cold Chain 2.0 system were designed to offer thermal stability and to have integrated sensor and communication systems. The containers are connected with, a cold chain cloud application providing real-time data whilst in transit.

The technology was adopted by AveXis, the developer of Zolgensma (onasemnogene abeparvovec-xioi), which is the first one-time gene therapy for the treatment of spinal muscular atrophy (SMA) in children less than two years old.

Novartis acquired AveXis​ in April 2018 for $8.7bn (€7.79bn) and led Zolgensma to receive approval​ from the US Food and Drug Administration (FDA) last month.

Currently, 44% of Savsu’s shares are owned by Biolife Solutions, which also has an exclusive option to purchase all remaining shares.

Mike Rice, CEO of BioLife, commented on the partnership with Savsu, saying that the company looks forward to additional announcements related to new Savsu customers.

Related news

Show more

Related products

Riding the mRNA Highway

Riding the mRNA Highway

Content provided by Thermo Fisher Scientific - Biosciences | 15-May-2023 | White Paper

Learn more about process development and manufacturing in the mRNA space to enable successful scale-ups of mRNA production for therapeutic applications.

Related suppliers

Follow us


View more